Table III.
Results of the cost-effectiveness analysis.
| Parameter | BEV+TMZ group | TMZ group |
|---|---|---|
| Costs for the PFS state, $ | 38,211.30 | 11,476.12 |
| Costs for the PD state, $ | 11,979.22 | 7,819.41 |
| Total costs, $ | 50,190.52 | 19,295.53 |
| Incremental costs, $ | 30,894.99 | / |
| Effectiveness for the PFS state, QALYs | 0.35 | 0.17 |
| Effectiveness for the PD state, QALYs | 0.36 | 0.36 |
| Total effectiveness, QALYs | 0.71 | 0.53 |
| Incremental effectiveness, QALYs | 0.18 | / |
| Total C/E, $/QALY | 70,690.87 | 36,406.66 |
| ICER, $/QALY | 171,638.83 | / |
BEV, bevacizumab; TMZ, temozolomide; PFS, progression-free survival; PD, progressive disease; QALY, quality-adjusted life year; C/E, cost-effectiveness; ICER, incremental cost-effectiveness ratio.